Even worse - with all the learnings from the previous trials for Covid ARDS and MIS-C focusing on inflammatory biomarkers - I'm sure the medical professionals now know which patients are going to need a life saving treatment beyond the SOC or they'll pass away. The progression of CRP, SAA etc show the patients that are desperately in need of Rem-L but unfortunately right now can't get it. It must be very difficult to be a medical professional in that situation.
Cell Therapy News/Articles, page-11055
-
- There are more pages in this discussion • 7,191 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |